Education
About Us
Working with TipRanks
Follow Us
Globus Medical (GMED)
NYSE:GMED
Top Page
Globus Medical
(NYSE:GMED)
Select Model
Select Model
Rating:80Outperform
Price Target:
$106.00
▲(17.18% Upside)
Action:ReiteratedDate:02/25/26
GMED scores well on financial strength and cash generation, reinforced by a positive earnings-call setup with reaffirmed revenue guidance and raised EPS expectations. Technicals support the trend (price above major moving averages), while the main constraint is valuation (P/E ~29.7) alongside execution/lumpiness risks noted in guidance and integration commentary.
Positive Factors
Conservative balance sheet
Globus’s very low leverage (debt-to-equity ~0.03 in 2025) and growth in equity/assets provide durable financial flexibility. This conservatism supports M&A, buybacks, or increased R&D without stressing liquidity, lowering financial risk and enabling steady capital allocation over the medium term.
Strong cash generation
Operating cash flow and FCF jumped materially in 2025, with free cash flow roughly 78% of net income historically. Reliable cash conversion underpins sustainable reinvestment in product development, supports integration funding and shareholder returns, and provides a buffer through business cycles.
Synergies and margin expansion
Globus has executed synergies ahead of plan and delivered marked margin expansion (adjusted gross margin ~69% in Q4), indicating scalable cost and operational efficiencies. Early synergy capture and margin improvement support sustainable profitability gains as acquisitions are integrated long term.
Negative Factors
Nevro integration risk
Although Nevro became EPS-accretive sooner than expected, management warns integration risks remain. Historic net losses at Nevro imply ongoing operational and margin work; integration shortfalls could erode expected synergies, inject volatility into results, and delay sustainable contribution to earnings.
Reduced liquidity from large cash uses
Significant uses of cash reduced the company’s liquidity buffer materially. Lower cash balances constrain optionality for bolt-on deals, larger CapEx, or defensive spending, increasing reliance on near-term cash generation to fund operations and strategic moves during unforeseen downturns or integration costs.
Profitability and revenue lumpiness
History of margin swings and management’s note on lumpiness in Enabling Technologies and placements indicate durable volatility in revenue recognition and profit. Such structural unevenness complicates forecasting, can pressure short-term capital allocation choices, and raises execution risk for sustained margin improvement.
Globus Medical (GMED) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$12.22B
Dividend YieldN/A
Average Volume (3M)1.68M
Price to Earnings (P/E)21.9
Beta (1Y)0.78
Revenue Growth11.75%
EPS Growth364.73%
CountryUS
Employees5,300
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)1.28
Shares Outstanding112,625,130
10 Day Avg. Volume1,610,796
30 Day Avg. Volume1,684,810
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.58
Price to Sales (P/S)4.02
P/FCF Ratio20.04
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue4.02
Enterprise Value/Gross Profit5.96
Enterprise Value/Ebitda14.45
Forecast
1Y Price Target
$108.54Price Target Upside19.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)4.35
Revenue Forecast (FY)$3.19B
Globus Medical Business Overview & Revenue Model
Company DescriptionGlobus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
How the Company Makes MoneyGlobus Medical generates revenue primarily through the sale of its spinal implant and surgical instrument products to hospitals and surgical centers. The company has a diversified revenue model that includes direct sales, as well as partnerships with distributors in various regions. Key revenue streams include the sale of its core products, which encompass a variety of spinal fusion systems, and biologic materials used in spinal surgery. Additionally, GMED invests in research and development to create new products and improve existing ones, which can lead to increased market share and higher sales. The company's strong focus on innovation, along with strategic partnerships and collaborations with healthcare providers, contributes significantly to its earnings by enhancing product offerings and expanding its reach in the medical device market.
Globus Medical Key Performance Indicators (KPIs)
Any
Revenue By Segment
Analyzes revenue from different business segments, highlighting which areas are driving growth and which may need strategic adjustments to improve performance.
Analyzes revenue from different business segments, highlighting which areas are driving growth and which may need strategic adjustments to improve performance.
Data provided by:
The Fly
The FlyGlobus Medical Earnings Call Summary
Earnings Call Date:Feb 24, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 12, 2026
Earnings Call Sentiment Positive
The call presented a largely positive picture: strong top- and bottom-line growth, record Q4 results, margin expansion, rapid synergy realization (NuVasive synergies ahead of plan), and earlier-than-expected accretion from Nevro. Management raised EPS guidance and reaffirmed revenue guidance for 2026 while outlining plans for continued R&D investment and capital placement flexibility. Offsetting these positives were early-year operational and Enabling Tech lumpiness, international supply chain and regional challenges, integration risk for Nevro, a meaningful decline in the cash balance due to acquisitions, debt paydown and buybacks, and temporary one-time charges. Overall, the highlights (robust revenue and profit growth, margin improvement, successful synergy capture, and raised guidance) outweigh the lowlights, which are largely short- to medium-term execution and integration issues.Q4-2025 Updates
Positive Updates
Record Quarterly and Annual Financial Performance
Q4 2025 revenue of $826.4M (+25.7% YoY, +24.7% constant currency) and full year 2025 revenue of $2.939B (+16.7% as-reported, +16.2% constant currency); Q4 non-GAAP EPS $1.28 (+52.1% YoY) and full year non-GAAP EPS $3.98 (+30.8% YoY).
Strong Base Business Growth
Q4 base business revenue $726.7M (+10.6% YoY) and consolidated base business organic growth in H2 2025 of 8.8%; U.S. Spine grew ~10% in Q4 with 48 consecutive weeks of growth, indicating durable above-market momentum.
Enabling Technologies Momentum
Q4 Enabling Technologies sales $55.6M (+18.5% YoY), achieved record sales in dollars and units for the capital portfolio and ExcelsiusGPS robotic system; pipeline deals closed in Q4 after earlier elongation.
Trauma and Product Launch Success
Trauma business grew ~27% in Q4 (26.8% reported) driven by legacy trauma uptake and demand for new launches such as the ANTHEM elbow plating system which has exceeded expectations.
Margin Expansion and Profitability
Adjusted gross profit margin expanded to 69.2% in Q4 2025 (vs. 67.1% prior year); legacy Globus adjusted EBITDA margin reached 35.7% in Q4 and consolidated adjusted EBITDA margin was 33.9%; full year adjusted EBITDA 31.3%.
Synergy Execution Outperforming Plan
Actioned $200M of NuVasive synergies (target $170M) ahead of schedule by ~$30M and achieved sequential improvements across the P&L; free cash flow generation increased ~150% from $81.8M (Q4 2023) to $202.4M (Q4 2025).
Nevro Integration and Accretion
Nevro added $293.6M revenue for the full year and $99.7M in Q4 with a stand-alone adjusted EBITDA margin of 21.2% in Q4; Nevro became EPS accretive within the first 9 months post-acquisition, 15 months ahead of initial guidance.
Improving GAAP Metrics and Debt Reduction
GAAP gross margin improved to 65.7% in Q4 (vs. 57.2% prior year), driven by lower inventory step-up amortization; fully repaid $450M convertible debt assumed in merger, reducing interest expense.
Capital Allocation and Shareholder Returns
During 2025 repurchased ~4.3M shares for $300.5M and repurchased $45M in Q4; $390M of share repurchase authorization remains under a $500M program while prioritizing internal investment and CapEx (guidance 5-6% of sales).
2026 Financial Guidance Upheld and EPS Raised
Reaffirmed 2026 revenue guidance of $3.18B to $3.22B (implied growth 8.2%–9.6%) and increased full-year non-GAAP EPS guidance to $4.40–$4.50 (implied growth 10.6%–13.1%), reflecting confidence in continued margin expansion.
Negative Updates
Early-Year Operational Headwinds and Lumpiness
2025 began with a disappointing Q1 and intermittent lumpiness in Enabling Technologies deals (elongated pipeline throughout the year), producing uneven quarter-to-quarter performance before a strong Q4 recovery.
International Supply Chain and Regional Challenges
Legacy Globus international spine was impacted by supply chain shortages early in 2025; APAC (including Japan) and parts of Latin America experienced choppiness, resulting in uneven international growth despite improvement by Q4 (+19% international revenue in Q4, +14.2% constant currency).
Cash Balance Decline and Large Uses of Cash
Cash, cash equivalents and marketable securities declined from $956.2M (12/31/2024) to $629.1M (12/31/2025), driven by $450M debt repayment, $252.5M Nevro acquisition, and $300.5M in share repurchases—reducing liquidity headroom.
Nevro Integration Risks and Short-Term Lumpiness
Management noted Nevro integration risk is not fully behind them; growth path may be non-linear in short term despite early accretion, and Nevro had posted a $113M net loss on $409M revenue in FY2024.
High SG&A and One-Time Charges
Consolidated SG&A in Q4 was $318.5M (38.5% of sales) including $13.4M of one-time estimated litigation charges; Nevro contributed $49.8M of SG&A in Q4 (49.9% of Nevro sales), indicating high relative selling expenses during integration.
Enabling Tech Revenue Recognition Risks from Lease Mix
Management plans greater use of operating leases and flexible deal structures to drive placements; while this supports adoption, it may defer or reduce immediate revenue recognition and make near-term revenue comparisons lumpy.
R&D Percentage Decline and Need to Ramp Investment
R&D fell to 5.0% of sales for full year 2025 (Q4 legacy Globus R&D 4.4% of sales) due to synergy captures; management plans to increase R&D to 5%–6% in 2026, which will pressure near-term margins versus current expansion trajectory.
Persistent Competitive and Market Uncertainties
Competitive landscape continues to evolve (new robotic/navigation entrants and industry divestitures); management acknowledges monitoring threats but intends to rely on product launches, sales hires and pricing/deal flexibility to mitigate risks.
Company Guidance
Globus reaffirmed full‑year 2026 revenue guidance of $3.18–$3.22 billion (implying growth of 8.2%–9.6% vs. 2025) and raised non‑GAAP diluted EPS guidance to $4.40–$4.50 (vs. prior $4.30–$4.40, implying EPS growth of 10.6%–13.1%), expects at least 100 bps of adjusted gross margin expansion to a full‑year 69%–70% (with a long‑term mid‑70s target), projects R&D of 5%–6% of sales, SG&A of 38%–39% of sales, CapEx of 5%–6% of sales, and a non‑GAAP tax rate of 24%–25%; management noted guidance contemplates a mix of cash sales and placements (including fair‑market‑value leases) that can affect near‑term revenue recognition, and that Nevro—now EPS‑accretive within the first nine months post‑acquisition—may remain lumpy in the short term but is expected to drive profitable growth over the medium to long term.Globus Medical Financial Statement Overview
Summary
Strong fundamentals supported by a very conservative balance sheet (low leverage) and improving cash generation (higher operating cash flow and free cash flow). Profitability rebounded sharply in 2025, but prior margin compression and some incomplete margin fields make earnings durability/consistency the main watch item.Income Statement
Revenue has scaled meaningfully over the period, with 2025 revenue up ~6% year over year. Profitability improved sharply in 2025, with net profit margin rising to ~18% versus ~4% in 2024, indicating a strong rebound in earnings power. Offsetting this, margins were notably higher earlier in the period (2021–2022) and compressed in 2023–2024, showing profitability can be volatile; additionally, 2025 gross profit and some margin fields appear incomplete in the provided data, limiting margin-based consistency checks.78
Positive
Balance Sheet
The balance sheet is conservatively positioned: debt is low relative to equity (debt-to-equity ~0.03 in 2025 vs ~0.13 in 2023–2024), providing substantial financial flexibility. Equity and assets have grown over time, supporting a stronger capital base. Return on equity improved to ~11.8% in 2025 (from ~2.5% in 2024), but the prior-year dip suggests returns can fluctuate even with low leverage.90
Very Positive
Cash Flow
Cash generation is solid and improving: operating cash flow rose to ~$753M in 2025 (from ~$521M in 2024) and free cash flow reached ~$589M, with strong growth versus the prior year. Cash conversion is generally healthy, with free cash flow running at ~78% of net income in both 2024 and 2025, supporting earnings quality. A watch item is variability in the relationship between cash flow and earnings across years (e.g., operating cash flow relative to net income was meaningfully lower in 2023–2024 than in other years), suggesting working-capital or timing swings.82
Very Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.94B | 2.52B | 1.57B | 1.02B | 958.10M |
| Gross Profit | 1.98B | 1.48B | 1.02B | 759.12M | 718.88M |
| EBITDA | 729.90M | 473.73M | 346.58M | 304.50M | 264.73M |
| Net Income | 537.90M | 102.98M | 122.87M | 190.17M | 149.19M |
Balance Sheet | |||||
| Total Assets | 5.30B | 5.25B | 5.09B | 2.08B | 1.96B |
| Cash, Cash Equivalents and Short-Term Investments | 557.24M | 890.06M | 517.79M | 446.06M | 443.45M |
| Total Debt | 118.66M | 537.19M | 520.40M | 6.01M | 0.00 |
| Total Liabilities | 729.51M | 1.07B | 1.09B | 229.75M | 215.88M |
| Stockholders Equity | 4.57B | 4.18B | 4.00B | 1.85B | 1.74B |
Cash Flow | |||||
| Free Cash Flow | 588.77M | 405.21M | 165.22M | 104.42M | 219.38M |
| Operating Cash Flow | 753.45M | 520.64M | 243.50M | 178.47M | 276.27M |
| Investing Cash Flow | -355.01M | -176.05M | 302.97M | -110.36M | -375.94M |
| Financing Cash Flow | -679.16M | -27.70M | -231.82M | -109.96M | 54.15M |
Globus Medical Technical Analysis
Neutral
90.46
Price Trends
90.79
Negative
83.35
Positive
70.79
Positive
Market Momentum
0.90
Negative
47.51
Neutral
34.14
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GMED, the sentiment is Neutral. The current price of 90.46 is below the 20-day moving average (MA) of 90.63, below the 50-day MA of 90.79, and above the 200-day MA of 70.79, indicating a neutral trend. The MACD of 0.90 indicates Negative momentum. The RSI at 47.51 is Neutral, neither overbought nor oversold. The STOCH value of 34.14 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GMED.
Globus Medical Risk Analysis
Globus Medical disclosed 52 risk factors in its most recent earnings report. Globus Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Globus Medical Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | $12.22B | 21.94 | 10.01% | ― | 11.75% | 364.73% | |
72 Outperform | $15.17B | 22.70 | 9.20% | 2.28% | 5.78% | 61.52% | |
72 Outperform | $146.14B | 41.38 | 15.08% | 0.95% | 10.95% | -18.32% | |
68 Neutral | $109.58B | 48.91 | 12.60% | ― | 21.62% | 54.80% | |
65 Neutral | $19.17B | 25.25 | 5.60% | 1.05% | 5.47% | -23.03% | |
64 Neutral | $29.26B | 24.78 | ― | 3.30% | -0.76% | -55.03% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
GMED
Globus Medical
90.46
11.64
14.77%
BSX
Boston Scientific
72.21
-32.50
-31.04%
PHG
Koninklijke Philips
30.93
4.61
17.50%
SNN
Smith & Nephew Snats
36.36
6.73
22.72%
SYK
Stryker
381.89
-11.15
-2.84%
ZBH
Zimmer Biomet Holdings
95.75
-7.97
-7.69%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.